Back grey_arrow_rt.gif
 
Archived NATAP Articles from June 2003
 
null.gif
 
 
  1. Treating Patients with Decompensated Cirrhosis: 20% sustained response rate - (06/30/03)

    2.  
  2. Comparison of 2 Regimens that Include Interferon--2a plus Ribavirin for Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus Coinfected Patients - (6/30/03)

    3.  
  3. Exercise and Vitamin E Intake Are Independently Associated with Metabolic Abnormalities in Human Immunodeficiency VirusPositive Subjects: A Cross-Sectional Study - (6/30/03)

    4.  
  4. Alcohol May Affect Progression of Hepatitis C & Interferon Efficacy - (6/30/03)

    5.  
  5. The differential immune responses during HBV and HCV infection: mechanisms of the diseases and response - (6/30/03)

    6.  
  6. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B - (6/30/03)

    7.  
  7. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C - (6/30/03)

    8.  
  8. CD4 & CD8 Resistance to HIV-Infection in IDUs - (6/30/03)

    9.  
  9. DDW Liver Conference Report - Written by Andrew Talal, MD, MPH, Cornell-Weill Medical Center GI & Hepatitis Clinic - (6/25/03)

    10.  
  10. Resistance Wksp - 3TC Residual Antiviral Activity Despite M184V Resistance - (6/25/03)

    11.  
  11. Identification of a Transmission Chain of HIV Type 1 Containing Drug Resistance-Associated Mutations - (6/25/03)

    12.  
  12. High Prevalence of Elevated Lipids Observed in Children on HAART - (6/25/03)

    13.  
  13. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy - (6/25/03)

    14.  
  14. Hepatitis Induced by Kava (Piper methysticum rhizoma) - (6/24/03)

    15.  
  15. The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count) - (6/24/03)

    16.  
  16. TMC-114, new protease inhibitor for PI resistance - (6/23/03)

    17.  
  17. Lamivudine in Adolescents with Hepatitis B - (6/23/03)

    18.  
  18. HEPATITIS B PRIMER - (6/23/03)

    19.  
  19. Monitoring of viral levels during therapy of hepatitis C: early response and discontinuing HCV therapy - (6/23/03)

    20.  
  20. Long-Term Mitochondrial Toxicity in HIV-Uninfected Infants Born to HIV-Infected Mothers - (6/23/03)

    21.  
  21. HIV Infection and Associated Risks Among Young Men Who Have Sex With Men in Miami Beach - (6/23/03)

    22.  
  22. Viagra Use in a Community-Recruited Sample of Men Who Have Sex With Men, San Francisco - (6/23/03)

    23.  
  23. Almost Half of All U.S. Adults Have Been Tested for HIV, CDC Study Says - (6/23/03)

    24.  
  24. Immune Reconstitution and Control of HIV Conference - Reported by Mike Youle, MD, Director, Centre for HIV Medicine at Royal Free Hospital, London, UK - (6/19/03)

    25.  
  25. Resistance Wksp - Short-Duration, Single-Drug Interruption Strategy - (6/19/03)

    26.  
  26. Resistance Wksp - Tenofovir Resistance at the HIV Drug Resistance Workshop - (6/17/03)

    27.  
  27. Almost Half of All U.S. Adults Have Been Tested for HIV, CDC Study Says - (6/16/03)

    28.  
  28. Resistance Wksp - Transmission of Drug Resistance in Newly Infected - (6/16/03)

    29.  
  29. Resistance Wksp - Genotype Testing Did Not Detect Low Level NNRTI Mutations and Tenofovir Resistance, Single-Drug Treatment Interruption, 3TC Efficacy Persists Despite Resistance - (6/16/03)

    30.  
  30. Resistance Wksp - TMC-125: a new NNRTI, early study results - (6/12/03)

    31.  
  31. Resistance Wksp - Elvucitabine (ACH-126,433, L-Fd4C) - (6/12/03)

    32.  
  32. Resistance Wksp - Super-Infection and Co-Infection - (6/12/03)

    33.  
  33. 12th International HIV Drug Resistance Workshop - (6/11/03)

    34.  
  34. Serostim (HGH) on Black Market for Body Builders - (6/11/03)

    35.  
  35. Treatment options for chronic hepatitis B not responding to interferon - (6/11/03)

    36.  
  36. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders - (6/11/03)

    37.  
  37. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature - (6/11/03)

    38.  
  38. Fatty Liver When ALT is Normal - (6/11/03)

    39.  
  39. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon - (6/11/03)

    40.  
  40. Dirty Needles Misjudged in AIDS in Africa - (6/11/03)

    41.  
  41. Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling - (6/11/03)

    42.  
  42. Inclusion body myositis: another possible manifestation of antiretroviral-associated mitochondrial toxicity - (6/5/03)

    43.  
  43. IL-12 Found Not Effective Against HCV - (6/4/03)

    44.  
  44. DDW - Hepatitis B Report from DDW Conference: adefovir, tenofovir, clevudine - (6/4/03)

    45.  
  45. DDW - PILOT STUDY OF PIOGLITAZONE IN NONALCOHOLIC STEATOHEPATITIS - (6/4/03)

    46.  
  46. Structured Treatment Interruption Study: final results Swiss Cohort Study - (6/2/03)

    47.  
  47. CDC Programs for Rapid HIV Testing & Controversy - (6/2/03)

    48.  
  48. Lamotrigine for HIV-associated painful sensory neuropathies: A placebo-controlled trial - (6/2/03)

    49.  
  49. Why HAART Doesn't Increase CD4s - (6/2/03)

    50.  
  50. Atazanavir in PI-Experienced Patients - (6/2/03)

    51.  
  51. Sperm Washing Technique in France: ART May Allow HIV-Infected Men to Father Children Without Infecting Their Partners - (6/2/03)

    52.